Evolus Inc., of Newport Beach, Calif., reported that second-quarter net revenue was $2.3 million and recognized upon delivery of Jeuveau (prabotulinumtoxinA-xvfs) for injection to customers. The gross margin was 71.4% and may fluctuate in the future due to various marketing programs, the company said. The product competes with Botox (onabotulinumtoxinA, Allergan plc) as well as Dysport (abobotulinumtoxinA, Galderma Laboratories LP) in treating severe glabellar (frown) lines associated with corrugator and/or procerus muscle activity in adults. Evolus ended the quarter with $99.9 million on its balance sheet. Company shares (NASDAQ:EOLS) closed Monday at $17.71, down 25 cents. (See BioWorld, Feb. 5, 2019.)

No Comments